Nct00074971 fabrazyme fabry?

NCT00074971 is a clinical trial identifier connected to Fabrazyme (agalsidase beta) for Fabry disease.

What is NCT00074971 and how is it related to Fabrazyme?

NCT00074971 refers to a study record on ClinicalTrials.gov that involves Fabrazyme (agalsidase beta), a disease-specific therapy used for Fabry disease. Fabrazyme is administered as an enzyme replacement to address the underlying deficiency of alpha-galactosidase A activity in patients with Fabry disease [1].

What kinds of Fabrazyme studies does this number usually fall under?

Trials of Fabrazyme in Fabry disease commonly include one or more of these themes:
- testing safety and tolerability
- evaluating changes in disease biomarkers (such as lyso-Gb3)
- assessing clinical outcomes across organ systems affected by Fabry disease (kidneys, heart, and sometimes pain-related symptoms) [1]

Why people search for “NCT00074971 Fabrazyme Fabry”

People often look up trial IDs like NCT00074971 to confirm details such as:
- who was eligible (age groups, baseline organ involvement, prior treatment history)
- whether the trial was completed or terminated
- what endpoints were measured and over what duration
- whether Fabrazyme was compared with placebo or another approach [1]

If you share the exact text you’re seeing next to NCT00074971 (or the ClinicalTrials.gov link), I can summarize the trial’s population, design, endpoints, and status more precisely.

Sources

1. ClinicalTrials.gov - NCT00074971